Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Motor neuron disease

A potential plasma biomarker for disease progression in amyotrophic lateral sclerosis

Nature Reviews Neurology volume 9, page 601 (2013)Cite this article

Subjects

Access through your institution
Buy or subscribe

An ELISA study has shown that plasma levels of antibodies against neurofilament (NF) proteins correlate with disease stage in amyotrophic lateral sclerosis (ALS). Elevated NF antibody levels were observed in patients with ALS compared with healthy controls. In addition, patients with advanced ALS exhibited higher levels of NF antibodies than did individuals at earlier stages of the disease. The results raise the possibility that NF immunoreactivity could be a biomarker for disease progression in ALS.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Puentes, F. et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry doi:10.1136/jnnp-2013-305494

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

A potential plasma biomarker for disease progression in amyotrophic lateral sclerosis. Nat Rev Neurol 9, 601 (2013). https://doi.org/10.1038/nrneurol.2013.218

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneurol.2013.218

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing